BlendsGrowth
CJC-1295 NO DAC 5mg + Ipamorelin 5mg
Peptide blend · GHRH analogue + GHS · Synthetic
FDA · CATEGORY 2 (2023) — BOTH COMPONENTS
Half-life
~2 hours
Short
minsdays
Route
SubQ injection
Evidence
Preclinical only
Risk
Standard
Reference only — not an endorsement.
Overview
Known for
Mechanism
Key facts
Format
Lyophilized powder
Mechanism targets
Classification
Secondary
Supply & nature
SecretagogueSecretagogue
FDA category
Category 2 (2023) — both components
Evidence & standing
Evidence base
Preclinical only
Risk level
Standard
Best studies
5 references
Dosage & protocol
Typical dose
100mcg
Cycle
Daily (night)
Onset
10 days first effects
Full effect
70 days
Half-life
~30min / ~2h
CJC: ~30 min | Ipa: ~2hrs | Combined effective window: 2-3hrs
Protocol
Time to effects
Recommended vial
Reference figures only
Dosing reflects published laboratory protocols and is not guidance for use in any living subject.
Safety
Reversibility
Fully Reversible
Side effects
Interactions
Handle with research caution
Storage & handling
Lyophilised
12–24 months
2–8°C
Reconstituted
4–6 weeks
2–8°C









